Curia viert baanbrekende ceremonie in Albuquerque
De bouw van de steriele fill-finish-uitbreiding voor de productie van vaccins en injecteerbare medicijnen begint
ALBANY, NY & ALBUQUERQUE, N.M.–(BUSINESS WIRE)– Curia, een toonaangevende organisatie voor contractonderzoek, ontwikkeling en productie, heeft vandaag een baanbrekende ceremonie georganiseerd om het begin te markeren van de bouw van de uitgebreide campus in Albuquerque, New Mexico. De extra ruimte zal een nieuwe, geavanceerde geïsoleerde high-speed fill-finish flaconlijn huisvesten – inclusief biosafety level 2 (BSL-2) insluiting, evenals twee lyofilisatoren voor de high-speed fill-finishlijn en een geïsoleerde flexibele vullijn voor injectieflacons, spuiten en patronen ter ondersteuning van geavanceerde therapieën in kleinere batches.
Dit persbericht bevat multimedia. Bekijk de volledige release hier: https://www.businesswire.com/news/home/202221027006125/en/
Curia Celebrates Ground-breaking Ceremony in Albuquerque
Construction begins on sterile fill-finish expansion for the production of vaccines and injectable medicines
ALBANY, N.Y. & ALBUQUERQUE, N.M.–(BUSINESS WIRE)– Curia, a leading contract research, development and manufacturing organization, today hosted a ground-breaking ceremony to mark the beginning of construction of its expanded campus in Albuquerque, New Mexico. The additional space will house a new, advanced isolated high-speed fill-finish vial line – which includes biosafety level 2 (BSL-2) containment as well as two lyophilizers for the high-speed fill-finish line and an isolated flexible filling line for vials, syringes, and cartridges to support smaller-batch advanced therapies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221027006125/en/
Left to right: City of Albuquerque Mayor Timothy M. Keller, New Mexico Governor Michelle Lujan Grisham, Curia Chairman and CEO John Ratliff, New Mexico Economic Development Cabinet Secretary Alicia J. Keyes, Curia Albuquerque Vice President and General Manager Jonathan Shoemaker. (Photo: Business Wire)
“We are delighted to recognize the beginning of construction for this much-needed expansion in bioscientific capacity and capabilities,” said Curia Chairman and CEO, John Ratliff. “I’m proud of the important work performed by Curia’s team here in Albuquerque, as they conduct the last step in the complex manufacturing process needed for injectable vaccines and medicines. Each day, they advance our mission of delivering life-changing life science as part of a broader community dedicated to improving health. The expansion will not only provide career opportunities in New Mexico, it enables Curia to make a greater contribution to the production of vaccines and treatments, potentially saving millions of lives locally, nationally and globally. We appreciate the support and collaboration of all the organizations represented at our ground-breaking celebration.”
The expansion was part of a cooperative agreement with the Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), the Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) and the U.S. Army Contracting Command’s Joint COVID Response Division (ACC-JCRD) to support the domestic production of injectable medicines. The State of New Mexico is also supporting the expansion through assistance from the Local Economic Development Act (LEDA) job creation fund. Curia is also eligible for state assistance for employee job training from JTIP, New Mexico’s Job Training Incentive Program.
Curia leadership partners contributing to today’s ground-breaking event included New Mexico Gov. Michelle Lujan Grisham, Economic Development Cabinet Secretary Alicia J. Keyes and Albuquerque Mayor Tim Keller.
The facility expansion is designed by Burns & McDonnell and will be constructed by BE&K Building Group. The flexible filling line and high-speed fill-finish vial line are planned to be operational in 2025.
About Curia
Curia is a leading contract research, development and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s 3,700 employees at 29 locations across the U.S., Europe, and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221027006125/en/
Contacts
Corporate Contact:
Sue Zaranek
Curia
+1 518 512 2111
corporatecommunications@CuriaGlobal.com
Media Communications:
Charya Wickremasinghe, Ph.D.
Brandwidth Solutions LLC
+1 832 776 9115